Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Cactus Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,195,004

171 payments

Through program year 2025, Cactus Clinical Research Inc is reported as receiving $1,195,004 in research payments, across 171 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $276,202 40
2024 Research $505,347 48
2023 Research $234,589 48
2022 Research $29,067 17
2021 Research $26,226 6
2020 Research $28,378 3
2019 Research $95,196 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $546,649 72 payments
  2. Mylan Inc. $274,213 23 payments
  3. Sumitomo Pharma America, Inc. $219,036 55 payments
  4. Pfizer Inc. $82,747 5 payments
  5. GRT US Holding, Inc. $23,464 6 payments
  6. Myovant Sciences Inc. $21,226 5 payments
  7. Noven Pharmaceuticals, Inc. $17,363 1 payment
  8. Myovant Sciences GmbH $5,307 3 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $5,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $274,213 23 payments
  2. Long-Term Safety Study of Elagolix in Combination With Estradiol Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $232,553 10 payments
  3. Study of Oral Elagolix Tablets in Combination With Combined Oral Contraceptive Capsules Tablets to Assess Dysmenorrhea Response in Adult Female Participants With Endometriosis and Associated Moderate to Severe Pain $131,987 18 payments
  4. A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $112,199 17 payments
  5. A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain $95,080 15 payments
  6. A Phase 3 Randomized Double Blind Placebo and Activecontrolled Multicenter Parallelgroup Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects With Chronic Low Back Pain $64,387 2 payments
  7. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $41,578 8 payments
  8. A Phase 3 Singlearm Openlabel Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $31,987 9 payments
  9. Serene $29,232 18 payments
  10. Kf7013-02 $23,464 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record